<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1076">
  <stage>Registered</stage>
  <submitdate>21/02/2006</submitdate>
  <approvaldate>21/02/2006</approvaldate>
  <nctid>NCT00294658</nctid>
  <trial_identification>
    <studytitle>Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy</studytitle>
    <scientifictitle>A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>1U01NS042685-01A2</secondaryid>
    <secondaryid>R01NS050733</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Myasthenia Gravis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - thymectomy plus prednisone
Treatment: drugs - prednisone alone

Active Comparator: Thymectomy plus prednisone - Procedure: Extended Transsternal Thymectomy plus prednisone treatment

Placebo Comparator: Prednisone alone - Drug: prednisone alone protocol


Treatment: surgery: thymectomy plus prednisone
The thymectomy will be performed as soon as possible after randomization.

Treatment: drugs: prednisone alone
Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time-weighted Average Quantitative Myasthenia Gravis Weakness Score Over 3 Years - Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. The time weighted average is a calculation that provides an integrated measure of the outcome over the time of followup. The denominator that was used to compute the time-weighted average for the Quantitative Myasthenia Gravis (QMG) score and the prednisone dose was the number of days from randomization to the last visit. Computations used the trapezoidal method where in the QMG score is multiplied by the number of days at this level from one visit to the next and added up over the entire followup experience and divided by the total number of days from randomization.</outcome>
      <timepoint>baseline, month 3, 4, 6 and every 3 months through 36 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time-weighted Average Alternate-day Prednisone Dose (mg) Measured Over 3 Years - Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period.</outcome>
      <timepoint>baseline, month 1 , 2 , 3, 4, 6 and every 3 months through 36 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Subgroup Analyses of Time-weighted Average Quantitative Myasthenia Gravis Score by Prednisone Use at Enrollment - Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease.</outcome>
      <timepoint>baseline, month 3, 4, 6 and every 3 months through 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subgroup Analyses of Time-weighted Average Quantitative Myasthenia Gravis Score by Sex - Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease.</outcome>
      <timepoint>baseline, month 3, 4, 6 and every 3 months through 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subgroup Analyses of Time-weighted Average Quantitative Myasthenia Gravis Score by Age at Disease Onset - Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease.</outcome>
      <timepoint>baseline, month 3, 4, 6 and every 3 months through 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subgroup Analyses of Time-weighted Average Alternate-day Prednisone Dose (mg) by Prednisone Use at Enrollment - Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period.</outcome>
      <timepoint>baseline, month 3, 4, 6 and every 3 months through 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subgroup Analyses of Time-weighted Average Alternate-day Prednisone Dose (mg) by Sex - Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period.</outcome>
      <timepoint>baseline, month 3, 4, 6 and every 3 months through 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subgroup Analyses of Time-weighted Average Average Alternate-day Prednisone Dose (mg) by Age at Disease Onset - Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period.</outcome>
      <timepoint>baseline, month 3, 4, 6 and every 3 months through 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Serious Adverse Events - Number of participant who experienced at least one serious adverse events over 3 years: Thymectomy plus prednisone n=25 (out of 66); Prednisone alone n=33 (out of 60)</outcome>
      <timepoint>baseline to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Patients With at Least One Serious Adverse Events - Number of participant who experienced at least one serious adverse events over 3 years: Thymectomy plus prednisone n=25 (out of 66); Prednisone alone n=33 (out of 60)</outcome>
      <timepoint>baseline to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Classification of Serious Adverse Events</outcome>
      <timepoint>baseline to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hospitalization for Exacerbation of Myasthenia Gravis</outcome>
      <timepoint>baseline to 2 years and baseline to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative Number of Hospital Days - Number who had hospitalization: Thymectomy plus prednisone n=15 (out of 66); Prednisone alone n=31 (out of 60)</outcome>
      <timepoint>baseline to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reason for Hospitalization According to Medical Dictionary for Regulatory Activities Term - Number who had hospitalization: Thymectomy plus prednisone n=15 (out of 66); Prednisone alone n=31 (out of 60)</outcome>
      <timepoint>baseline to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time-weighted Average Prescribed Alternate Day Prednisone Dose (mg) - Physicians reported prescribed alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prescribed prednisone dosages had been weighted over the days of reporting period.</outcome>
      <timepoint>baseline-day 20, month 1,2, 3, 4, 6 and every 3 months through 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Penalized Time-weighted Average Alternative Day Prednisone Dose (mg; Method 1: Penalized Using Maximum Dose Before Azathioprine) - For each participant who took azathioprine, we penalized them by taking the maximum dose of prednisone before azathioprine was added. We then applied the same method to compute the time-weighted alternative day prednisone dose from baseline, month 3, 4, 6 and every 3 months through 36 months.</outcome>
      <timepoint>baseline, month 3, 4, 6 and every 3 months through 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Penalized Time-weighted Average Alternative Day Prednisone Dose (mg; Method 2: Penalized Using Dose at Time of Starting Azathioprine) - For each participant who took azathioprine, we penalized them by taking the prednisone dose at the time azathioprine commenced. We then applied the same method to compute the time-weighted alternative day prednisone dose from baseline, month 3, 4, 6 and every 3 months through 36 months.</outcome>
      <timepoint>baseline, month 1 , 2 , 3, 4, 6 and every 3 months through 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time-Weighted Average MG Activity of Daily Living (MG-ADL) - MG Activity of Daily Living total scores range from 0 to 24, with the lower scores indicating better daily living quality of life.</outcome>
      <timepoint>baseline, month 4, 6 and every 3 months through 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time-Weighted Average MG Activity of Daily Living (MG-ADL) at Month 12, 24, and 36 - MG Activity of Daily Living total scores range from 0 to 24 by visit, with the lower scores indicating better daily living quality of life.</outcome>
      <timepoint>Month 12, 24, and 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Azathioprine Use</outcome>
      <timepoint>baseline to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Exchange Use</outcome>
      <timepoint>baseline to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intravenous Immunoglobulin Use</outcome>
      <timepoint>baseline to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minimal Manifestation (MM) Status at Month 12, 24 and 36 - Number of participants who were in minimal manifestation status at month 12, 24 and 36.</outcome>
      <timepoint>Month 12, 24 and 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative Days in Hospital for Myasthenia Gravis Exacerbation - Number of patients with MG exacerbation: Thymectomy plus prednisone=6 (out of 66); Prednisone alone=17 (out of 60)</outcome>
      <timepoint>baseline to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative Days in Hospital for Myasthenia Gravis Exacerbation - Number of patients with MG exacerbation: Thymectomy plus prednisone=6 (out of 66); Prednisone alone=22 (out of 60)</outcome>
      <timepoint>baseline to 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Short Form-36 Standardized Physical Component - Range from 0 to 100, the higher the physical component value, the better the mental health.</outcome>
      <timepoint>Month 0, Month 12, Month 24 and Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Short Form-36 Standardized Mental Component - Range from 0 to 100, the higher the mental component value, the better the mental health.</outcome>
      <timepoint>Month 0, Month 12, Month 24 and Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Associated Complications (TAC) - Treatment associated complications measured complications occurred by myasthenia gravis patients. Report number of participant with at least one complications by each visit.</outcome>
      <timepoint>Month 0, 1, 2, 3, 4 then every 3 months through Month 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Associated Symptoms (TAS) - Treatment associated symptoms measured myasthenia gravis symptoms such as back pain and/or bruises. Report number of participant with at least one treatment associated symptoms by each visit.</outcome>
      <timepoint>Month 0, 1, 2, 3, 4 then every 3 months through Month 36</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male and female MG patients age greater than 18 and less than 65 years

          -  Onset of generalized MG within the last 5 years

          -  Positive serum anti-acetylcholine receptor binding antibodies (muscle acetylcholine
             receptors, AchRAb =/&gt; 1.00 nmol/L. AchRAb levels of 0.50-0.99 nmol/L will be
             acceptable if there is another confirmatory test for MG, including single-fiber
             electromyography (EMG), repetitive nerve stimulation, or unequivocal edrophonium
             testing.)

          -  MGFA class II-IV at entry, using the MG Foundation of America (MGFA) classification,
             while receiving optimal anti-cholinesterase treatment with or without oral prednisone</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Ocular MG without generalized weakness (MGFA Class I) or minimal weakness that would
             not require the use of corticosteroids

          -  Myasthenic weakness requiring intubation (MGFA Class IV) in the prior month

          -  Immunosuppressive therapy other than corticosteroids in the preceding year

          -  Medically unfit for thymectomy

          -  Chest CT evidence of thymoma.

          -  Pregnancy or lactation; contraindications to the use of corticosteroids, unless
             postmenopausal or surgically sterile. Women considering becoming pregnant during the
             period of the study are to be excluded.

          -  A serious concurrent medical, neurological or psychiatric condition that would
             interfere with thymectomy or subsequent clinical assessments

          -  Current alternate day dose of prednisone &gt; than 1.5 mg/kg or 100 mg or the equivalent
             daily doses (&gt; 0.75 mg/kg or 50 mg).

          -  Participation in another experimental clinical trial

          -  History of alcohol or drug abuse within the 2 years prior to randomization.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>126</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>University of Sydney, Royal Prince Alfred Hospital and The University of Sydney - Sydney</hospital>
    <hospital>University of Melbourne, Melbourne, The Royal Melbourne Hospital, Dept of Neurology, Royal Melbourne Hospital - Victoria</hospital>
    <postcode> - Sydney</postcode>
    <postcode>3050 - Victoria</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Vermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Brasilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Curitiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio De Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-W체rttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bavaria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>North Rhine-Westphalia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rhineland-Palatinate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>M체nster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>T체bingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ishikawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyushu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wojew처dztwo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>New Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Alabama at Birmingham</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Institute of Neurological Disorders and Stroke (NINDS)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to determine if thymectomy combined with prednisone therapy is
      more beneficial in treating non-thymomatous myasthenia gravis than prednisone therapy alone.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00294658</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gary Cutter, PhD</name>
      <address>University of Alabama at Birmingham School of Public Health, Department of Biostatistics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>